View ValuationT.Man Pharmaceutical 향후 성장Future 기준 점검 1/6T.Man Pharmaceutical은 연간 수입과 매출이 각각 4.6%와 8.6% 증가할 것으로 예상되고 EPS는 연간 4.7%만큼 증가할 것으로 예상됩니다.핵심 정보4.6%이익 성장률4.67%EPS 성장률Pharmaceuticals 이익 성장15.0%매출 성장률8.6%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트14 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 18First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: EPS: ฿0.29 (down from ฿0.30 in 1Q 2025). Revenue: ฿633.7m (up 5.8% from 1Q 2025). Net income: ฿114.6m (down 6.0% from 1Q 2025). Profit margin: 18% (down from 20% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • May 01Upcoming dividend of ฿0.32 per shareEligible shareholders must have bought the stock before 08 May 2026. Payment date: 26 May 2026. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 2.5%. Lower than top quartile of Thai dividend payers (7.5%). Higher than average of industry peers (1.9%).Reported Earnings • Mar 02Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ฿1.31. Revenue: ฿2.53b (up 14% from FY 2024). Net income: ฿523.1m (up 16% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.Declared Dividend • Mar 02Final dividend of ฿0.32 announcedShareholders will receive a dividend of ฿0.32. Ex-date: 8th May 2026 Payment date: 26th May 2026 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Payout Ratios Payout ratio: 17%. Cash payout ratio: 73%.공시 • Feb 27T.Man Pharmaceutical Public Company Limited Proposes Interim Cash Dividend for the Period from January 1, 2025 to December 31, 2025, Payable on May 26, 2026T.Man Pharmaceutical Public Company Limited proposed to the 2026 Annual General Meeting of Shareholders to acknowledge the interim dividend payment that has already been paid during the year, and it is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the allocation of profits for the payment of the remaining cash dividend at the rate of THB 0.32 per share, totaling THB 128,001,152 for the Company's ordinary shares of 400,003,600 shares Paid from Operating period from January 1, 2025 to December 31, 2025. Such dividend will be paid from the Company's unallocated net profit, which is the net profit of the business that has paid corporate income tax at the rate of 20%. In this regard, individual shareholders are entitled to tax credits in calculating dividend tax according to Section 47 bis of the Revenue Code. The annual dividend payment for 2025, including both the interim dividend and this dividend, represents 60.78% of the net profit for the year 2025. In this regard, the Board has resolved to set the Record Date for shareholders entitled to receive dividends on 11 May 2026, and the dividend payment date on 26 May 2026. However, the right to receive such dividend is subject to approval from the 2026 Annual General Meeting of Shareholders. Ex-dividend date: May 8, 2026.공시 • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026, at 14:00 SE Asia Standard Time.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.28 (vs ฿0.32 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.28. Revenue: ฿661.4m (up 23% from 3Q 2024). Net income: ฿112.6m (up 8.1% from 3Q 2024). Profit margin: 17% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • Aug 19Upcoming dividend of ฿0.24 per shareEligible shareholders must have bought the stock before 26 August 2025. Payment date: 09 September 2025. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Thai dividend payers (7.9%). In line with average of industry peers (1.7%).Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.27 (vs ฿0.30 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.27. Revenue: ฿535.5m (up 2.8% from 2Q 2024). Net income: ฿106.8m (up 8.0% from 2Q 2024). Profit margin: 20% (in line with 2Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ฿0.30 (down from ฿0.42 in 1Q 2024). Revenue: ฿599.0m (up 1.7% from 1Q 2024). Net income: ฿121.9m (down 13% from 1Q 2024). Profit margin: 20% (down from 24% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Asia.공시 • May 08T.Man Pharmaceutical Public Company Limited announces Annual dividend, payable on May 23, 2025T.Man Pharmaceutical Public Company Limited announced Annual dividend of THB 0.1800 per share payable on May 23, 2025, ex-date on May 06, 2025 and record date on May 07, 2025.Reported Earnings • Feb 27Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: ฿1.31. Revenue: ฿2.23b (up 12% from FY 2023). Net income: ฿450.7m (up 4.5% from FY 2023). Profit margin: 20% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%.공시 • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025, at 14:00 SE Asia Standard Time.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿12.60, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Pharmaceuticals industry in Asia.Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: ฿0.31 (vs ฿0.33 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.31. Revenue: ฿535.8m (up 13% from 3Q 2023). Net income: ฿104.2m (up 16% from 3Q 2023). Profit margin: 19% (in line with 3Q 2023).공시 • Oct 23T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion.T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,994,100 Price\Range: THB 16.3 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,005,900 Price\Range: THB 16.3Board Change • Oct 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측SET:TMAN - 애널리스트 향후 추정치 및 과거 재무 데이터 (THB Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20272,977555N/AN/A112/31/20262,757504N/AN/A13/31/20262,561516N/AN/AN/A12/31/20252,526523110336N/A9/30/20252,376449306483N/A6/30/20252,250441350505N/A3/31/20252,236433341516N/A12/31/20242,226451346520N/A9/30/20242,197433313514N/A6/30/20242,130419239416N/A3/31/20242,089445195384N/A12/31/20231,98043162282N/A9/30/20231,90341697387N/A6/30/20231,982494269597N/A3/31/20232,003483279560N/A12/31/20222,025473289524N/A12/31/20211,26356196276N/A12/31/202090160129194N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TMAN 의 연간 예상 수익 증가율(4.6%)이 saving rate(2.2%)보다 높습니다.수익 vs 시장: TMAN 의 연간 수익(4.6%)이 TH 시장(10.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: TMAN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: TMAN 의 수익(연간 8.6%)이 TH 시장(연간 9.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: TMAN 의 수익(연간 8.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TMAN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:24종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스T.Man Pharmaceutical Public Company Limited는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Theethanat JindaratYuanta Securities (Thailand) Company LimitedKritawit RatanakhanokchaiYuanta Securities (Thailand) Company LimitedAthitaya ChinakanjanaditYuanta Securities (Thailand) Company Limited1명의 분석가 더 보기
Reported Earnings • May 18First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: EPS: ฿0.29 (down from ฿0.30 in 1Q 2025). Revenue: ฿633.7m (up 5.8% from 1Q 2025). Net income: ฿114.6m (down 6.0% from 1Q 2025). Profit margin: 18% (down from 20% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • May 01Upcoming dividend of ฿0.32 per shareEligible shareholders must have bought the stock before 08 May 2026. Payment date: 26 May 2026. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 2.5%. Lower than top quartile of Thai dividend payers (7.5%). Higher than average of industry peers (1.9%).
Reported Earnings • Mar 02Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ฿1.31. Revenue: ฿2.53b (up 14% from FY 2024). Net income: ฿523.1m (up 16% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
Declared Dividend • Mar 02Final dividend of ฿0.32 announcedShareholders will receive a dividend of ฿0.32. Ex-date: 8th May 2026 Payment date: 26th May 2026 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Payout Ratios Payout ratio: 17%. Cash payout ratio: 73%.
공시 • Feb 27T.Man Pharmaceutical Public Company Limited Proposes Interim Cash Dividend for the Period from January 1, 2025 to December 31, 2025, Payable on May 26, 2026T.Man Pharmaceutical Public Company Limited proposed to the 2026 Annual General Meeting of Shareholders to acknowledge the interim dividend payment that has already been paid during the year, and it is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the allocation of profits for the payment of the remaining cash dividend at the rate of THB 0.32 per share, totaling THB 128,001,152 for the Company's ordinary shares of 400,003,600 shares Paid from Operating period from January 1, 2025 to December 31, 2025. Such dividend will be paid from the Company's unallocated net profit, which is the net profit of the business that has paid corporate income tax at the rate of 20%. In this regard, individual shareholders are entitled to tax credits in calculating dividend tax according to Section 47 bis of the Revenue Code. The annual dividend payment for 2025, including both the interim dividend and this dividend, represents 60.78% of the net profit for the year 2025. In this regard, the Board has resolved to set the Record Date for shareholders entitled to receive dividends on 11 May 2026, and the dividend payment date on 26 May 2026. However, the right to receive such dividend is subject to approval from the 2026 Annual General Meeting of Shareholders. Ex-dividend date: May 8, 2026.
공시 • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026, at 14:00 SE Asia Standard Time.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.28 (vs ฿0.32 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.28. Revenue: ฿661.4m (up 23% from 3Q 2024). Net income: ฿112.6m (up 8.1% from 3Q 2024). Profit margin: 17% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • Aug 19Upcoming dividend of ฿0.24 per shareEligible shareholders must have bought the stock before 26 August 2025. Payment date: 09 September 2025. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Thai dividend payers (7.9%). In line with average of industry peers (1.7%).
Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.27 (vs ฿0.30 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.27. Revenue: ฿535.5m (up 2.8% from 2Q 2024). Net income: ฿106.8m (up 8.0% from 2Q 2024). Profit margin: 20% (in line with 2Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ฿0.30 (down from ฿0.42 in 1Q 2024). Revenue: ฿599.0m (up 1.7% from 1Q 2024). Net income: ฿121.9m (down 13% from 1Q 2024). Profit margin: 20% (down from 24% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Asia.
공시 • May 08T.Man Pharmaceutical Public Company Limited announces Annual dividend, payable on May 23, 2025T.Man Pharmaceutical Public Company Limited announced Annual dividend of THB 0.1800 per share payable on May 23, 2025, ex-date on May 06, 2025 and record date on May 07, 2025.
Reported Earnings • Feb 27Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: ฿1.31. Revenue: ฿2.23b (up 12% from FY 2023). Net income: ฿450.7m (up 4.5% from FY 2023). Profit margin: 20% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%.
공시 • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025, at 14:00 SE Asia Standard Time.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿12.60, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Pharmaceuticals industry in Asia.
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: ฿0.31 (vs ฿0.33 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.31. Revenue: ฿535.8m (up 13% from 3Q 2023). Net income: ฿104.2m (up 16% from 3Q 2023). Profit margin: 19% (in line with 3Q 2023).
공시 • Oct 23T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion.T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,994,100 Price\Range: THB 16.3 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,005,900 Price\Range: THB 16.3
Board Change • Oct 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.